Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui to Build $240 Million Biopharma Plant in Jiangsu

publication date: Sep 14, 2015
Jiangsu Hengrui Medicine will invest $240 million to build an internationally compliant biopharmaceutical production facility in its home city of Lianyungang, Jiangsu Province. The company has acquired a 200 acre site in the Lianyungang Technological Development Zone for the plant. Two months ago, Hengrui announced plans to spend $137 million building a new biologic drug manufacturing facility in Suzhou. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital